World Investment Advisors raised its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 17.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 59,122 shares of the company's stock after buying an additional 8,578 shares during the quarter. World Investment Advisors' holdings in Sanofi were worth $3,279,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Lee Danner & Bass Inc. purchased a new position in Sanofi during the fourth quarter worth about $31,000. Bessemer Group Inc. boosted its holdings in Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after acquiring an additional 242 shares during the last quarter. Golden State Wealth Management LLC boosted its holdings in Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after acquiring an additional 545 shares during the last quarter. UMB Bank n.a. boosted its holdings in Sanofi by 30.7% in the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after acquiring an additional 264 shares during the last quarter. Finally, Wayfinding Financial LLC acquired a new position in Sanofi in the first quarter valued at $63,000. Hedge funds and other institutional investors own 14.04% of the company's stock.
Sanofi Stock Up 0.0%
Shares of NASDAQ SNY traded up $0.02 during midday trading on Monday, reaching $48.32. 2,305,572 shares of the company's stock were exchanged, compared to its average volume of 2,338,380. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12. The stock has a market capitalization of $118.50 billion, a PE ratio of 17.26, a price-to-earnings-growth ratio of 1.05 and a beta of 0.48. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. The business's fifty day moving average price is $50.61 and its two-hundred day moving average price is $52.12.
Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The company's revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.78 earnings per share. Analysts forecast that Sanofi will post 4.36 EPS for the current year.
Sanofi Increases Dividend
The company also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were issued a $2.0369 dividend. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. The ex-dividend date was Friday, May 9th. Sanofi's payout ratio is currently 56.79%.
Analyst Upgrades and Downgrades
Several research firms have commented on SNY. BNP Paribas began coverage on Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective on the stock. The Goldman Sachs Group began coverage on Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective on the stock. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Morgan Stanley set a $56.00 price objective on Sanofi in a research report on Monday, June 2nd. Finally, Barclays reissued an "overweight" rating on shares of Sanofi in a research report on Wednesday. Three research analysts have rated the stock with a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $61.50.
Read Our Latest Research Report on SNY
Sanofi Company Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Stories
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
